Pluristem announces peer-reviewed article on Cytotherapy
Pluristem Therapeutics announced the publication of a peer-reviewed article in Cytotherapy, the official journal of the International Society for Cellular Therapy, titled, "Placenta-Derived PLX-PAD Mesenchymal-Like Stromal Cells are Efficacious in Rescuing Blood Flow in Hind Limb Ischemia Mouse Model by a Dose- and Site-Dependent Mechanism of Action, or MOA." The article is based on the Company's preclinical findings and will be published in the December 2017 issue of Cytotherapy. The study utilized a mouse model of hind limb ischemia, or HLI, to study the efcacy and MOA of PLX-PAD cells in the treatment of peripheral artery disease, or PAD. Pluristem is currently conducting a global, pivotal Phase III study in critical limb ischemi, CLI, and is expecting clinical data from its Phase II study in intermittent claudication, IC. Both are forms of peripheral artery disease. In both conditions, blood supply to the legs is obstructed, leading to impaired blood ow and tissue ischemia.